Frontier BiotechnologiesSHSE:688221 +6.64%71 Days Payable is 199.48 as of Mar. 2026, which is 92% above its 10-year median of 104.09. GuruFocus rates SHSE:688221 with a GF Score™ of 71/100 and a GF Value™ of ¥37.33 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 922 Drug Manufacturers companies, Frontier Biotechnologies ranks better than 75.6% on this metric.
The historical rank and industry rank for Frontier Biotechnologies's Days Payable or its related term are showing as below:
SHSE:688221'
s Days Payable Range Over the Past 10 Years
Min: 51.65 Med: 104.09 Max: 151.42
Current: 151.42
During the past 12 years, Frontier Biotechnologies's highest Days Payable was 151.42. The lowest was 51.65. And the median was 104.09.
SHSE:688221's Days Payable is ranked better than 75.6% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.455
vs SHSE:688221: 151.42
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Frontier Biotechnologies's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Frontier Biotechnologies Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Frontier Biotechnologies's Days Payable distribution charts can be found below:
* The bar in red indicates where Frontier Biotechnologies's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Frontier Biotechnologies's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Frontier Biotechnologies (SHSE:688221) has a Days Payable of 199.48 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Frontier Biotechnologies and its competitors. This is 92% above median its historical median of 104.09. Over the past decade, Frontier Biotechnologies' Days Payable has ranged from 51.65 to 151.42. According to the industry distribution chart, Frontier Biotechnologies ranks #225 out of 922 companies in the Drug Manufacturers industry, placing it in the top 24.4%.
Is Frontier Biotechnologies' Days Payable too high?
Frontier Biotechnologies' current Days Payable of 199.48 is 92% above median its 10-year median of 104.09. Over the past 10 years, this metric has ranged from a low of 51.65 to a high of 151.42. The Drug Manufacturers industry median Days Payable is 90.46. Frontier Biotechnologies' value of 199.48 is 120.5% above this industry median. Based on the distribution chart, Frontier Biotechnologies ranks #225 out of 922 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Frontier Biotechnologies has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Frontier Biotechnologies' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Frontier Biotechnologies ranks #225 out of 922 companies for Days Payable. This places Frontier Biotechnologies in the top 24% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.46. Frontier Biotechnologies' value of 199.48 is 120.5% above this benchmark. Historically, Frontier Biotechnologies' own Days Payable has ranged from 51.65 to 151.42 over the past decade. While the company's 10-year median is 104.09 vs. the industry median of 90.46, Frontier Biotechnologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.46, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Frontier Biotechnologies's current Days Payable of 199.48 is 120.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Frontier Biotechnologies and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Frontier Biotechnologies's current Days Payable is 199.48, which is 92% above median its own 10-year median of 104.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Frontier Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Frontier Biotechnologies (SHSE:688221) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥37.33, compared to a current price of ¥27.30 — trading 26.9% below its estimated fair value. The current Days Payable is 199.48, which is 92% above median its 10-year median of 104.09 and 120.5% above the Drug Manufacturers industry median of 90.46. Frontier Biotechnologies' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Frontier Biotechnologies (SHSE:688221), the current Days Payable is 199.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Frontier Biotechnologies (SHSE:688221) Overvalued in 2026?
Based on GuruFocus' analysis, Frontier Biotechnologies stock appears to be undervalued.
The current stock price of ¥27.30 is trading 26.9% below its estimated GF Value™ of ¥37.33.
GuruFocus considers Frontier Biotechnologies to be Modestly Undervalued.
Key valuation signals for SHSE:688221:
Days Payable: 199.48 (92% above median its 10-year median of 104.09)
GF Value™: ¥37.33 vs. price of ¥27.30 (26.9% below fair value)
Industry Position: 120.5% above the Drug Manufacturers median (#225 of 922)
No single metric tells the full story. See the SHSE:688221 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688221 has been successfully added to your 
